Skip to main content
Fig. 2 | BMC Musculoskeletal Disorders

Fig. 2

From: Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial

Fig. 2

a b and c Measured B and T lymphocyte counts at baseline and at 24 weeks. a Memory B lymphocyte counts (CD 19+ 27+) at baseline and 24 weeks. Leflunomide shows significant difference in Memory B lymphocytes (CD19 + 27+) at 24 weeks compared to baseline (P < 0.01). Rituximab shows significant difference of Memory B lymphocytes (CD19 + 27+) at 24 weeks compared to baseline (p < 0.001). b Mean B lymphocyte counts (CD 19) at baseline and 24 weeks. Leflunomide shows no significant difference in B lymphocyte counts (CD19) at 24 weeks compared to baseline (P > 0.05). Rituximab shows significant difference in B lymphocyte counts (CD 19) at 24 weeks compared to baseline (p = <0.001). c T lymphocyte counts (CD 3) in patients at baseline and 24 weeks. Leflunomide shows no significant difference in T lymphocyte counts (CD 3) at 24 weeks compared to baseline (P > 0.05). Rituximab shows no significant difference in T lymphocyte counts (CD 3) at 24 weeks compared to baseline (P > 0.05). Data Analysed using non-parametric Wilcoxan Rank Sum test as paired samples

Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us